for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sellas Life Sciences Group Inc

SLS.OQ

Latest Trade

3.02USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

2.76

 - 

82.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.02
Open
--
Volume
--
3M AVG Volume
9.28
Today's High
--
Today's Low
--
52 Week High
82.00
52 Week Low
2.76
Shares Out (MIL)
5.74
Market Cap (MIL)
17.50
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Cvi Investments Inc Reports 9.9% Passive Stake In Sellas Life Sciences Group As Of Jan 9, 2020 - SEC Filing

Sellas Life Sciences Group Says Informed By Nasdaq It Regained Compliance With Minimum Bid Price Requirement

SELLAS Life Sciences Reports Q3 Loss Per Share $2.68

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sellas Life Sciences Group Inc

SELLAS Life Sciences Group, Inc., formerly Galena Biopharma, Inc., is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company's NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company's therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient's own immune system.

Contact Info

15 W 38th St Fl 10

+1.917.4384353

https://www.sellaslifesciences.com/

Executive Leadership

Jane Wasman

Independent Chairman of the Board

Angelos M. Stergiou

President, Chief Executive Officer, Director

Barbara A. Wood

Executive Vice President, General Counsel, Corporate Secretary

John Thomas Burns

Principal Accounting Officer, Vice President - Finance, Controller

David A. Scheinberg

Director

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-3,539.646

2017

-521.948

2018

-122.488

2019(E)

-9.705
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
1.30
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-118.90
Return on Equity (TTM)
-84.05

Latest News

Latest News

BRIEF-Sellas Life Sciences Files For Offering Of Up To $30 Mln

* SELLAS LIFE SCIENCES GROUP INC FILES FOR OFFERING OF UP TO $30 MILLION - SEC FILING Source text: (https://bit.ly/2klt2uI) Further company coverage:

BRIEF-Sellas Life Sciences Receives FDA Orphan Drug Designation For Galinpepimut-S For Treatment Of Multiple Myeloma

* SELLAS LIFE SCIENCES RECEIVES FDA ORPHAN DRUG DESIGNATION FOR GALINPEPIMUT-S (GPS) FOR TREATMENT OF MULTIPLE MYELOMA (MM) Source text for Eikon: Further company coverage:

BRIEF-Sellas Life Sciences Ceases Gregory Torre's Employment As Chief Regulatory Officer

* SELLAS LIFE SCIENCES GROUP- ON APRIL 19, CO AND GREGORY TORRE, AGREED THAT HIS EMPLOYMENT AS CHIEF REGULATORY OFFICER WOULD CEASE - SEC FILING

BRIEF-Sellas Life Sciences Announces Appointment Of Gene Mack As Chief Financial Officer & Treasurer

* SELLAS LIFE SCIENCES ANNOUNCES APPOINTMENT OF GENE MACK AS CHIEF FINANCIAL OFFICER & TREASURER

BRIEF-Sellas Life Sciences Announces Positive Interim Data From Phase 2B Neuvax Clinical Trial In Combination With Herceptin

* SELLAS LIFE SCIENCES ANNOUNCES POSITIVE INTERIM DATA FROM PHASE 2B NEUVAX™ (NELIPEPIMUT-S) CLINICAL TRIAL IN COMBINATION WITH HERCEPTIN® IN HER2 1+/2+ BREAST CANCER PATIENTS

BRIEF-Sellas Life Sciences Announces $10.7 Mln Private Placement

* SELLAS LIFE SCIENCES ANNOUNCES $10,700,000 PRIVATE PLACEMENT

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up